Leo Pharma acquires worldwide rights to dersimelagon for up to $435M
Danish drugmaker Leo Pharma agreed to acquire worldwide rights to dersimelagon, a late-stage drug candidate for two rare genetic skin diseases, from Tanabe Pharma for up to $435 million in upfront and milestone payments.
·2 sources
